Last reviewed · How we verify
NCT05526040: HaNIS
Immunonutrition Supplementation in Head and Neck Cancer Patients Undergoing Cancer Treatment Study
NA trial testing Immunonutrient-enriched oral nutrition supplementation in Head and Neck Cancer in 116 participants. Status unknown.
30 June 2023
Quick facts
| Lead sponsor | University of Malaya |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 116 |
| Start date | 1 November 2022 |
| Primary completion | 30 June 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 2 locations across Malaysia |
Drugs / interventions tested
- Immunonutrient-enriched oral nutrition supplementation
- Standard medical nutrition therapy
Conditions studied
- Head and Neck Cancer — all drugs for Head and Neck Cancer →
Sponsor
University of Malaya
Who can join
18 and older, any sex, with Head and Neck Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, randomized, open-label intervention study to evaluate the effectiveness of immunonutrition supplementation in head and neck cancer (HNC) patients during cancer treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05526040
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Head and Neck Cancer
Currently open trials in the same condition.
- NCT07318220 — Prehabilitation Protocol for Head and Neck Cancer Patients · NA · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07467083 — Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Unde · Phase 3 · recruiting
- NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
- NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting
Other University of Malaya trials
Trials by the same sponsor.
- NCT07398066 — DEXmedetomidine for Postoperative Analgesia and Delirium Prevention After NEUROsurgery (DEX-NEURO Trial) · NA · not yet recruiting
- NCT07522463 — Enhancing Attention and Processing Speed Through Home-based Music Rehabilitation Program After Stroke in Malaysia · NA · not yet recruiting
- NCT07341802 — Pilot Feasibility Study of a Fall Prevention Exercise Programme for Community-dwelling Older Adults in Nanchang, China · NA · recruiting
- NCT07452705 — Small Study Comparing Two Pain Medicines in Teenagers for Pain Control After Scoliosis Corrective Surgery. · NA · not yet recruiting
- NCT07369596 — Impact of Chemotherapy Dose Reductions on Survival Outcomes Among Older NSCLC Patients Without Actionable Mutations · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05526040 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Malaya
- Last refreshed: 2 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05526040.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing